Scaling approaches for the prediction of human clearance of LNA-i-mir-221: A retrospective validation
{{output}}
LNA-i-miR-221 is a novel microRNA(miRNA)-221 inhibitor designed for the treatment of human malignancies. It has recently undergone phase 1 clinical trial (P1CT) and early pharmacokinetics (PKs) data in cancer patients are now available. We previously used mult... ...
